Skip to main content
. 2021 Mar 12;2021(3):CD013316. doi: 10.1002/14651858.CD013316.pub2

Barbagallo 2014.

Study characteristics
Study design Cohort
Study setting Setting: Department of Neurosurgery, Policlinico "G. Rodolico" Policlinico "G. Rodolico" University Hospital, University of Catania
Country: Italy
Dates: surgery between 2004 and 2012
Selection of participants All people underwent surgery for primary GBM with the aid of neuronavigation, and all but 2 people received gross tumour resection. The study was aimed at comparing short‐term vs long‐term TMZ treatment (people who received > 6 cycles), therefore some data were given as group A vs group B based on duration of treatment.
Participant characteristics Sample size: 37 (deaths: NR)
Age: mean 60.4, SD 11.8; range 30–82 years
Sex: 51.4% men
KPS: mean 67.1, SD 15.2
Tumour characteristics GBM: 100%
First diagnosis: 100%
Biopsy: 0%; subtotal resection: 5.4%; total resection: 94.6%
IDH1 wild‐type: NR; IDH2 wild‐type: NR
Treatment regimen Stupp protocol. For adjuvant TMZ therapy, people in Group A received TMZ every 28 days for > 6 cycles (up to 101), those in Group B were treated with the same adjuvant TMZ dose regimen for ≤ 6 cycles.
MGMT promoter methylation tests implemented MSP, PSQ
Dates and follow‐up Timing of MGMT assessment: NR
Start time for follow‐up: date of surgery; follow‐up: median NR; range NR
Notes